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Abstract
b-cell replacement may efficiently cure type 1 diabetic (T1D) patients whose insulin-secreting b-cells have been selectively
destroyed by autoantigen-reactive T cells. To generate insulin-secreting cells we used two cell sources: rat multipotent adult
progenitor cells (rMAPC) and the highly similar rat extra-embryonic endoderm precursor (rXEN-P) cells isolated under rMAPC
conditions from blastocysts (rHypoSC). rMAPC/rHypoSC were sequentially committed to definitive endoderm, pancreatic
endoderm, and b-cell like cells. On day 21, 20% of rMAPC/rHypoSC progeny expressed Pdx1 and C-peptide. rMAPCr/HypoSC
progeny secreted C-peptide under the stimulus of insulin agonist carbachol, and was inhibited by the L-type voltage-
dependent calcium channel blocker nifedipine. When rMAPC or rHypoSC differentiated d21 progeny were grafted under the
kidney capsule of streptozotocin-induced diabetic nude mice, hyperglycemia reversed after 4 weeks in 6/10 rMAPC- and 5/
10 rHypoSC-transplanted mice. Hyperglycemia recurred within 24 hours of graft removal and the histological analysis of the
retrieved grafts revealed presence of Pdx1-, Nkx6.1- and C-peptide-positive cells. The ability of both rMAPC and HypoSC to
differentiate to functional b-cell like cells may serve to gain insight into signals that govern b-cell differentiation and aid in
developing culture systems to commit other (pluripotent) stem cells to clinically useful b-cells for cell therapy of T1D.
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Introduction
Type 1 diabetes (T1D) is caused by the selective loss of
pancreatic b-cells by autoantigen-reactive T cells. The only way to
permanently restore normoglycemia in T1D is by b-cell replace-
ment through transplantation of an intact pancreas or isolated islet
cells [1]. However, shortage of donors is one of the major limiting
factors for treatment of T1D. Therefore, many groups are
evaluating whether b-cells differentiated from stem cells could be
an alternative cell source for b-cell replacement in T1D patients.
The pancreas is derived from definitive endoderm (DE), that
specifies from pluripotent cells in the blastocyst stage of the
embryo by a two-step process, wherein mesendoderm (ME) is
generated to the exclusion of ectoderm, followed by specification
to CXC chemokine receptor type 4 (Cxcr4) and SRY-related
HMG-box (Sox)17 expressing DE [2]. Specification to pancreatic
endoderm is associated with expression of Pancreatic and
duodenal homeobox 1 (Pdx1). The expression of Pdx1 is regulated
by the upstream transcription factor (TF) Hepatocyte nuclear
factor (Hnf)6 [3], that also stimulates expression of the pro-
endocrine gene, Neurogenin (Ngn)3 [4]. Other TFs important for
b-cell differentiation include Paired box gene (Pax)4, that specifies
endocrine pancreatic cells to a b-cell [5], NK6 homeobox (Nkx6).1
that regulates b-cell development [6]. Musculo aponeurotic
fibrosarcoma oncogene homolog A (MafA) is expressed initially
at e13.5 and is found only in insulin-positive cells during
development or in mature islets. MafA is thought to act in
conjunction with other known insulin enhancer regulatory factors
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(Neurogenic differentiation 1 (NeuroD1) and Pdx1) to promote
transcription of the insulin gene [7].
Pancreas versus liver specification in the foregut is at least in
part determined by Bone morphogenetic protein (BMP)4 and
Fibroblast growth factors (FGF)2 produced by the adjacent cardiac
mesoderm [8,9]. Pancreas commitment from ventral as well as
dorsal foregut endoderm is inhibited by Sonic hedgehog (SHH).
Activin-A and FGF2 represses SHH expression in pre-pancreatic
endoderm and facilitates endoderm formation [10]. Factors that
guide final differentiation to b-cells has also been identified, being
the most important Epidermal growth factor receptor (Erb)B1-3
[11], as well as Epidermal growth factor (EGF), Transforming
growth factor (TGF)b, heparin-binding EGF, betacellulin (BTC)
[12], and Growth and differentiation factor (GDF)11 [13,14].
Exendin-4, a long-acting analogue of glucagon like peptide-1, up-
regulates the expression of Pdx1 in human fetal islet clusters [15].
A number of studies have tested if embryonic stem cells (ESC)
can be guided in vitro to b-cell like cells that would then be suitable
for treatment of DM [16–20]. These studies have shown that
although definitive endoderm and pancreatic endoderm commit-
ment is readily achievable, full maturation towards functional,
single insulin-positive b-cells in vitro remains difficult [21].
Nevertheless, some studies have shown that grafting of the
partially committed and mixed m/hESC progeny in hyperglyce-
mic mice can reverse diabetes after several weeks, even though in a
number of studies teratoma formation was found [19], and in
other studies, chiefly exocrine pancreatic tissue was found rather
than endocrine pancreatic cells [21].
We described that multipotent adult progenitor cells (MAPC)
isolated from rat bone marrow (rBM), can -like m/hESC- be
guided to the hepatocyte-lineage, by sequential specification to
ME, DE, hepatic endoderm and then hepatocytes [22,23]. This
formed the basis for studies described here wherein we tested if
these cells can also be specified to insulin-secreting b-cells. Aside
from evaluating rMAPC, we also evaluated the differentiation
potential of rat extra-embryonic progenitor cells (rXEN-P) [24],
isolated directly from rat blastocysts using rMAPC culture
conditions (termed hypoblast stem cells or rHypoSC) [25]. Like
rMAPC [25,26], rHypoSC are a homogenous population of
SSEA1/CD31-positive cells that express aside from Oct4 also a
number of nascent hypoblast genes including FoxA2, Gata
binding protein (Gata)6, Gata4, and Hnf1b, but not Nanog or
Sox2, typical for ESC, caudal type homeobox 2 (Cdx2), typical for
trophoblast or Hnf4a and aFetoprotein (aFP), typical for primitive
endoderm (PrE). Like rMAPC, rHypoSC differentiate robustly to
mesodermal cells and hepatic endodermal cells.
We here describe that two different cell lines of both rMAPCs
and rHypoSCs can be committed to b-cell like cells using a four
step protocol. This yields mixed progeny that contains a fraction of
glucose responsive b-cell like cells and that reverses hyperglycemia
upon grafting under the kidney capsule of nude streptozotocin
(STZ)-treated mice.
Materials and Methods
Mice
Nude Balb/C mice were bred and housed in pathogen-free
animal facilities at the University of Navarra. All the mice had free
access to water and food. Animal procedures were performed
following the criteria outlined in the Guide of the Care and Use of
Laboratory Animals by the National Academy of Sciences. All
procedures were approved by the animal experimentation ethics
committee of the University of Minnesota, the Katholieke
Universiteit Leuven and the University of Navarra (Permit
Number: CEEA/105-10). All surgical procedures were performed
under isoflurane anesthesia, and all efforts were made in order to
minimize suffering.
Cell isolation and culture
MAPCs were isolated from BM of Fisher rats (strain F344/
IcoCrl) (Charles River, Wilmington, MA, USA). 1 to 4 week-old
rats were used for isolation as described in detail in a protocol
paper that was published recently [27]. Two rMAPC lines
rMAPC-1 and Clone 19 (CL-19) were used in this study. For
the isolation of blastocyst-derived XEN-P cells under MAPC
culture conditions, in brief, blastocysts obtained from the Fisher
rats were plated on flat-bottom Nunc 4-well plates (1 blastocyst/
well, 0.5 ml medium/well) under rMAPC culture conditions. After
2–10 cells, cells with refractile morphology appeared, which could
be expanded into cell lines by passaging on fibronectin-coated
100-mm dishes in rMAPC expansion medium. The rHyPoSc lines
Fi2 and Wk8 were used in this study [25].
Cytokines and growth factors used
The following cytokines and growth factors (all from R&D
Systems unless mentioned) were added for cell expansion or
during differentiation: rh/m/r Activin-A (338-AC), rhBMP4 (314-
BP), mLIF (Millipore, ESG1107), rhFGF2 (233-FB), Cyclopamine
(Biomol Research Lab, GR-334), betacellulin (1025-CE), Nicotin-
amide (Sigma, N0636), Exendin-4 (Sigma, E7144), GDF-11 (1958-
GD), rhHGF (294-HGN), hPDGF-BB (220-BB), mEGF (R&D
Systems 2028-3G) and monoclonal anti-human/mouse SHH N-
terminal peptide antibody (MAB 4641).
In vitro pancreas differentiation protocol
The pancreas differentiation protocol was carried out in four
steps as shown in Figure 1A. Differentiation medium contains 60%
DMEM low glucose, 40% MCDB, 2% fetal bovine serum,
16ITS+1 (Sigma, I2521), 0.1 mM ascorbic acid 2-phosphate,
50 mM 2-mercaptoethanol, 100 units of penicillin, and 1000 units
of streptomycin (all from Gibco BRL).
Step 1 [day 1 to 3]. rMAPCs or rHypoSCs were plated at
55,000–65,000 cells/cm2 on 24-well plates coated with 2%
matrigel (BD) in expansion medium. 6–12 h later, medium was
removed, cells were washed twice with PBS (Lonza), and
differentiation medium containing activin A (100 ng/mL) and
BMP-4 (50 ng/mL) was added.
Step 2 [day 3 to 9]. On day 3, media was exchanged for
differentiation medium containing activin A (100 ng/mL), BMP-4
(50 ng/mL), and anti-SHH (2.5 mg/mL).
Step 3 [day 9 to 15]. On day 9, cells were washed twice with
PBS and differentiation medium containing EGF (50 ng/mL) and
heparan sulfate (50 ng/mL) (Sigma, H9902) was added.
Step 4 [day 15 to 21]. On day 15, cells were washed twice
with PBS and differentiation medium with Exendin-4 (10 nM),
betacellulin (50 ng/mL) and GDF-11 (50 ng/mL) was added. On
day 18, a half media change was performed. To preserve the
floating clusters in the culture, discarded medium was centrifuged
(300 g, 5 min), cells were recovered and added again to the wells
together with fresh medium.
Real-time quantitative PCR (RT-qPCR)
RNA was obtained using the RNeasy Mini extraction kit
(Qiagen, 74104) according to the manufacturer’s instructions. The
RNA extracted was quantified and 1 mg RNA/reaction was
reverse transcribed to cDNA synthesis using Superscript III First-
Strand synthesis system (Invitrogen 18080-051) with the following
reaction conditions: first step, 25uC for 10 min; second step, 48uC
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for 30 min; and third step, 95uC for 5 min. The cDNA obtained
underwent 40 rounds of amplification (Eppendorfrealplex/ABI
7000 (Eppendorf)) with the following reaction conditions: 40 cycles
of a two-step polymerase chain reaction (PCR; 95uC for 15 min,
60uC for 60 min) after initial denaturation (95uC for 10 min) with
2 ml of cDNA solution (20 ng), 16SYBR Green Platinum SYBR
green qPCRSupermix-UDG (Invitrogen 11733-046) and 200 nM
of each primer in a 12 ml total volume reaction. mRNA levels were
normalized using GAPDH as housekeeping gene (TaqMan
Rodent GAPDH Control Reagent, Applied Biosystems). List of
primers used in this study has been mentioned in Table S4.
FACS analysis of Pdx1 protein expression
For flow cytometry analysis (FACSAria, BD Biosciences), cells
were harvested and washed twice with PBS and fixed for 10 min at
room temperature in 4% paraformaldehyde (PFA, Sigma) in PBS.
After fixation, cells were washed twice again with PBS. Later, in
order to permeabilize the nuclear membrane, the cell pellet was
resuspended in a PBS buffer containing 0.1% of saponin (Sigma,
S7900) plus 0.4% of Fish Skin Gelatin (FSG; Sigma, G7765).
Primary antibodies were diluted in PBS+0.4% FSG and incubated
for 20 minutes at room temperature. Secondary antibodies were
diluted in PBS+0.4% FSG and incubated for 15 minutes at room
temperature. The following antibodies and dilutions were used:
rabbit anti-Pdx1, 1:1,000 (a kind gift from Dr.Wright, Vanderbilt
University), AlexaFluor 594 anti-rabbit, 1:500 (Molecular Probes,
A11072).
Western blot analysis
b-cell like clusters derived from rMAPCs were harvested on day
21 of differentiation by centrifugation (300 g, 5 min) and washed
with PBS twice. Cell pellet was resuspended in lysis buffer (10 mM
TrisHCl pH 8.0, 150 mMNaCl, 1 mM EDTA, 1% NP40, 0.5%
deoxycholate, 0.1% SDS) supplemented with a cocktail of protease
inhibitors (Roche) and 100 mM of phenylmethanesulfonyl fluoride
(PMSF, Roche). Proteins were separated on Bis-Tris polyacryl-
amide gels, transferred by electroblotting onto PDVF membranes
(BioRad) and detected using an horseradish-peroxidase conjugated
secondary antibodies and chemiluminescent (ECL Plus, Amer-
sham) exposure of BioMax film (Kodak). For the primary
antibody, a rabbit anti-rat Pdx1 antibody was used a dilution of
1:5,000–1:10,000.
C-peptide release assays
Rat C-peptide levels in culture supernatants or cell lysates were
measured using the specific and ultrasensitive C-peptide ELISA
from Wako (Code No. 295–57401, Richmond, VA USA). C-
peptide release was measured by incubating either rMAPCs
clusters (day 21 after initial differentiation), rat islets or rat
insulinoma cell line (RIN) in Krebs-Ringer bicarbonate buffer
(KRBB) containing 120 mM NaCl, 5 mM KCl, 1.1 mM MgCl2,
25 mM NaHCO3, and 0.1% bovine serum albumin. First hour
incubation with KRBB solution was used as a washing step;
medium was discarded and then we performed one hour
incubation in KRBB containing 5 mM D-glucose or different
stimulation conditions: 20 mM D-glucose, 10 mM D-glucose,
5 mM D-Glucose plus carbachol (100 mM: Sigma, C4382) or
20 mM D-glucose plus nifedipine (50 mM; Sigma, N7634) or
10 mM L-Arginine (Sigma). After one hour incubation, KRBB
samples were stored at 220C. For C-peptide intracellular content,
C-peptide was extracted from the cells with acid ethanol (10%
glacial acetic acid in absolute ethanol) overnight at 220C followed
by cell sonication. Both C-peptide release and C-peptide
intracellular content were assayed using C-Peptide ELISA kit
(Wako, Japan) according to the manufacturer instructions.
Immunocytochemistry
For immunostaining, cells were washed twice with PBS and
fixed for 10 min at room temperature in 4% paraformaldehyde
(PFA) (Sigma) in PBS. After fixation, cells were washed three times
with PBS. Cells were permeabilized for 30 minutes using PBS
containing 0.2% Triton X-100 (PBST) (Acros Organics, New
Jersey) to permeabilize the nuclear membrane. To block unspecific
staining, cells were incubated 30 min in PBS containing 0.4% of
Fish Skin Gelatin (FSG; Sigma). Primary antibodies were diluted
in Dako antibody diluent (Dako, Glostrup, Denmark) and
incubated overnight and were further washed with PBST and
were incubated with secondary antibody for 1 hour at room
temperature. 1 mg/ml Hoechst 33258 (Sigma-Aldrich) was used
for nuclear staining.
For graft analysis, paraffin sections (5 mm thick) were rehydrated
using standard procedures and fixed using 10% Neutral Buffered
Formalin (NBF) for 15 minutes at room temperature and was
permeabilized using PBST (Acros Organics). Nonspecific blocking
was carried out with 10% serum corresponding to the animal
source of secondary antibody (Dako) for 30 minutes. Primary
antibodies were diluted with Dako antibody diluent and the cells
were incubated overnight at 4uC followed by incubation with
secondary antibodies conjugated with Alexa dyes (Invitrogen) for
1 hr at room temperature. Hoechst 33258 (Sigma-Aldrich) was
added along with secondary antibody incubation for nuclear
staining.
Following are the secondary antibodies and dilutions used in
this study: goat anti-rabbit AlexaFluor 594, 1:500 (Invitrogen,
Carlsbad, CA); rabbit anti-goat AlexaFluor 594, 1:500 (Invitro-
gen); goat anti-mouse AlexaFluor 594, 1:500 (Invitrogen); goat
anti-rabbit AlexaFluor 488, 1:500 (Invitrogen); rabbit anti-goat
AlexaFluor 488, 1:500 (Invitrogen); goat anti-mouse AlexaFluor
488, 1:500 (Invitrogen).
Intraperitoneal glucose tolerance test (GTT)
Transplanted (rMAPC, n= 6, rHypoSc, n = 4) and non-
transplanted (n= 4) nude Balb/C male mice were fasted overnight
(16–18 h), weighed, and injected with D-glucose (Sigma) at a dose
of 2 g/kg body weight intraperitoneally. Blood samples (50 mL)
were obtained from the tail vein before and at 5, 10, 15 20, 25, 30,
45, 60, 75, 90 and 120 minutes after glucose administration. Blood
glucose levels were analyzed by using a Glucometer Elite XL
(Bayer).
Figure 1. Gene expression profile of rMAPC and rHypoSC progeny at different stages during the differentiation protocol. (A)
Schematic representation of the four stage pancreas differentiation protocol and the genes expected to be expressed at each stage of the protocol.
In addition, light microscopy pictures of cell morphology at the end of each step of differentiation. RT-qPCR results of rMAPC-1 (B) and rHypoSC line
Fi2 (C) progeny for ME/DE marker genes (Mixl1, Eomes, Gsc, FoxA2, Sox17, and Oct4) endoderm gene markers (Hnf1b, Hnf4a, Nkx2.2, Nkx6.1 and Pax4)
pancreas progenitor gene markers (Hnf6, Pdx1, Hxbl9, Ngn3, NeuroD1) and Islet genes (Isl1, Ins1, Ins2, Glp-1R, ABCC8, Glut2, Sst, Ghr) at different time-
points during the pancreas differentiation protocol. Results are represented as mean 6 SE from n= 3 independent differentiations. * p,0.05;
** p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0063491.g001
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Cell transplantation
Experimental diabetes was induced in 8- to 10-week-old male
nude Balb/C mice by a single intravenous injection of STZ
(220 mg/kg of body weight) (Sigma) freshly dissolved in 0.1 M of
citrate buffer, pH 4.5 (Sigma). Stable hyperglycemia (blood
glucose levels 450–600 mg/dL) usually developed 48 to 72 hours
after STZ injections. In addition, insulin-pellets (Linco, Canada)
were implanted subcutaneously to prevent excessive glucose levels.
rMAPC or rHypoSC derived b-cell like cell clusters were
collected on day 21 of differentiation by centrifugation (300 g,
5 min) and washed with PBS twice. 56105 differentiated cells were
implanted under the left kidney capsule of ketamine/xylazine-
anesthetized STZ-treated mice. The weight of animals was
followed daily as well as the glucose concentrations, measured
on blood collected from the tail vein using a Glucometer Elite XL
(Bayer). Once animals had become normoglycemic, grafts were
removed by unilateral nephrectomy. Before and after nephrecto-
my, blood samples were obtained to determine the C-peptide
levels (Wako, Japan).
Statistics
At appropriate places results are expressed as mean fold change
6 S.E.M. The Gaussian distribution was confirmed using the
Shapiro-Wilk test. In experiments where data differences between
two groups were assessed, statistical significance was analyzed
using the Student’s unpaired t test. In order to compare the means
of multiple groups ANOVA test was performed. For non-
parametric data, the Kruskal-Wallis and Mann-Whitney tests
were used. All statistical analyses were performed using the
GraphPad Instat software version 3.00 for Windows (GraphPad
Software, San Diego, CA, USA). All p values ,0.05 were
considered statistically significant.
Results
Signals required for induction of Pdx1 and Ins gene
expression in rMAPC-1
To develop a protocol for rMAPC/rHypoSC differentiation to
b-cells, we initially used the rMAPC-1 cell line. We first tested the
effect of cell density, different types of extracellular matrix coating
and different concentrations of growth factors or inhibitors known
to affect endoderm specification, including bFGF, activin-A,
BMP4, retinoic acid (RA), cyclopamine and anti-SHH antibodies
(Ab) alone or in combinations, on the induction of Pdx1 expression
on d6 in the rMAPC-1 cell line [22,26]. Pdx1 mRNA not present
in undifferentiated rMAPC, was optimally induced on d6 when
rMAPC were plated on matrigel and exposed for 6 days to
100 ng/mL activin-A and 50 ng/mL BMP-4, combined with
10 mM cyclopamine or 2.5 mg/mL anti-SHH Ab from d3-d6
(Figure S1A).
Subsequently, d6 committed rMAPC progeny were cultured for
an additional 6 days with either EGF, heparan sulphate, FGF7,
FGF10 or BTC. Only when cultured in the presence of EGF and
heparan sulfate did we detect a further 4-fold increase in Pdx1
transcript levels by d12 (Figure S1B).
To induce final maturation to insulin-expressing cells, we
subsequently exposed on d12 rMAPC progeny to nicotinamide,
exendin-4, GDF11 and/or BTC-all considered to be pancreatic b-
cell maturation factors, alone or in combination. We evaluated the
effect by measuring transcripts for Pdx1 as well as Insulin (Ins)1 and
Ins2 on d18. Transcript levels of Pdx1 and Ins2 were highest when
GDF-11, BTC and Exendin-4 were added. However, Ins1 levels
were similarly induced when the following combinations were
used: GDF11 and nicotinamide; GDF11, nicotinamide and
betacellulin or GDF11, exendin-4 and betacellulin (Figure S1C)
for the last 6 days of differentiation.
Further optimization was obtained by adjusting the duration of
the different steps along the differentiation. As we observed
extensive cell death when cyclopamine was added between d3 and
d6, but not with anti-SHH Ab. Subsequent studies employed anti-
SHH Ab that supported the differentiation process similarly to
cyclopamine.
rMAPC lines differentiate towards endocrine islet cells by
a sequence of developmentally predicted steps
All subsequent studies were done using two previously described
lines, CL19 and rMAPC-1 [22,26,27]. The protocol designed in
the present study is represented schematically in Figure 1A and in
detail in material and methods. Under this standardized condi-
tions, small areas of epithelioid cells could be detected from d9. By
d19 (step 4), these epithelioid patches detached to form clusters of
50–150 cells floating in the culture supernatant. Therefore, on
d21, RT-qPCR analysis was performed on adherent cells and on
the clusters in the suspension.
We followed the transcript levels for genes expressed in ME/
DE, pancreatic endoderm, endocrine pancreatic endoderm and
mature islets by RT-qPCR on d3, d6, d9, d15, d18 and d21 (for
rMAPC-1 see Figure 1B and Table S1, for CL19, see Table S2).
Transcripts for the ME/DE marker genes, Goosecoid (Gsc),
Eomesodermin (Eomes) Mix1 homeobox-like 1(Mixl1) and Cxcr4 were
induced maximally between d6 and d9, and decreased upon
removal of Activin-A. Foxa2 and Sox17, already present in
undifferentiated rMAPC, persisted throughout the culture.
Expression of other endoderm TFs, Hnf1a and Hnf4b, increased
progressively during differentiation, whereas levels of Hnf1b,
already high in rMAPC, persisted throughout differentiation
(Figure 1B and Tables S1 & S2).
Transcript levels of Hnf6 increased from d3 of differentiation,
persisting till d21 (Figure 1B). Consistent with the increase in Hnf6,
Pdx1 expression became detectable from d3 onwards reaching
levels in the d21 non-adherent clusters approaching 10% of those
found in mature b-cells. Hlxb9 transcript levels progressively
increased till d21, to levels 10 fold higher than in mature b-cells.
Ngn3, was induced from d9 onwards, and persisted also in the d21
non-adherent clusters. Expression of NeuroD1 increased from d18
onwards, reaching maximal levels on d21 in the non-adherent
clusters. Pax4 and Nkx2.2 transcripts rose from d15 onwards and
Nkx6.1 from d18 in the 3D clusters to levels similar to those in b-
cells (Figure 1B and Tables S1 & S2).
Ins1 and Ins2 mRNA became detectable on d15, reaching levels
of 0.1% of b-cells in the non-attached clusters on d21 (Figure 1B).
We could not detect glucagon (Gcg) transcripts, but transcripts for
Somatostatin (Sst) and Ghrelin (Ghr) increased on d18 and d21,
respectively, to levels 0.08% and 0.1% of mature islets. Day 21
progeny also expressed insulin gene enhancer protein (Isl1) and ATP-
binding cassette transporter sub-family C member 8 (ABCC8) transcripts at
levels near those in b-cells, whereas levels of Glucose transporter 2
(Glut2) and Glucagon-like peptide 1 receptor (GLP1R) were between 1
and 5% this in primary b-cells. Transcripts for amylase were not
detected (Figure 1B and Tables S1 & S2).
It should be noted that aside from pancreatic endoderm and
more mature b-cell transcripts, transcripts coding for alpha-
fetoprotein (aFP) were induced from d3 onwards, transcripts for
the PrE TF Sox7 persisted throughout differentiation, while
transcript levels of albumin increased significantly less. aFP levels
were, however, significantly lower in d21 non-adherent clusters
compared with earlier time points. VE-Cadherin and Flk1 were
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expressed from d9 and d18 onwards and were also expressed in
the non-adherent clusters (Tables S1 & S2 and Figure S3).
Immunostaining demonstrated that on d21, 84%64 expressed
FoxA2, 21%63 Pdx1, 14%61 MafA and 7%61 C-peptide,
although the staining intensity of C-peptide per cell was low
(Figure 2A). Of note MafA expression appeared to be more
perinuclear than nuclear, consistent with the notion that the cells
generated were immature b-cell like cells [28]. Presence of Pdx1-
positive cells in the non-adherent clusters on d21 was confirmed by
FACS (Figure S2A; average percent positive cells 25%60.07), and
western blot (Figure S2B).
Like rMAPCs, rHypoSC also differentiate into insulin-
expressing cells
As rHypoSC have a similar gene expression profile and
differentiation ability in vitro compared with rMAPC [25], we
tested if the protocol used for rMAPC would also induce
commitment of blastocyst-derived rHypoSC towards pancreatic
endoderm and b-cell like cells in vitro. Studies were done using two
independently derived cell lines, Fi2 and WK8. Like rMAPC,
commitment of rHypoSC occurred via the initial activation of
ME/DE genes, followed by sequential activation of pancreatic and
endocrine pancreatic transcripts, among others Hnf6 from d3
onwards, Pdx1 from d9, and Ngn3, NeuroD1 and Nkx6.1 from d15
onwards (see Figure 1C and Table S3). The expression pattern of
Abcc8, Glut2, and Ins1 was similar to the expression pattern seen in
rMAPC progeny (Figure 1C). Expression of FoxA2, Pdx1, MafA
and C-peptide was confirmed at the protein level by immuno-
staining (Figure 2B).
Differentiated rMAPC and rHypoSC progeny show
regulated insulin secretion in vitro
We next determined if differentiated rMAPC and rHypoSC
progeny secrete C-peptide in response to glucose. In an initial set
of studies we stimulated rMAPC-1 progeny between d16 and d24
with a daily pulse of 20 mM glucose for 1 h and examined the
kinetics of C-peptide release. The secreted C-peptide levels
increased gradually and reached a peak level of 1.75 ng/mL on
d21–22, coincident with the peak levels for Ins1 and Ins2 mRNA
expression (Figure S4). C-peptide secretion increased significantly
when differentiated rMAPC-1 were subjected to increased glucose
concentrations (from 5 to 20 mM) on d21 or following stimulation
with 10 mM of the aminoacid, L-arginine (Figure 3A).
We also examined the effect of the muscarinic cholinergic
receptor agonist, carbachol [29], and L-type Ca2+ channel
blocker, nifedipine [30], on insulin secretion. Carbachol stimulat-
ed C-peptide release in the presence of low concentration of
glucose (5 mM), whereas nifedipine inhibited C-peptide secretion
Figure 2. Immunostaining of rMAPC and rHypoSC progeny. Fluorescence micrographs showing expression of FoxA2, Pdx1, MafA and C-
peptide in d21 rMAPC-1 (A) and Fi2 (B) differentiated progeny. Scale bars, 100 mm. Representative for n = 3 independent differentiations. Merge
indicate FoxA2, Pdx1, MafA and C-peptide together with DAPI staining.
doi:10.1371/journal.pone.0063491.g002
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in the presence of high glucose concentrations (20 mM) in both
rMAPC-1 and rHypoSC (Fi2) progeny (Figures 3B & 3C).
rMAPC and rHypoSC progeny normalize blood glucose
levels in streptozotocin (STZ)-diabetic mice
We next tested if rMAPC and rHypoSC progeny could reverse
hyperglycemia in vivo. Nude mice were injected with STZ to
eliminate endogenous b-cells, and received an implantable insulin
pellet to control excessive hyperglycemia. On day 762 following
STZ injection, 56105 (rMAPC-1 n= 5; CL19 n= 5; Fi2 n= 5;
WK8 n= 5) d21 non-adherent cells were grafted under the kidney
capsule of the mice. The weight and blood glucose levels of mice
were followed every other day after the cells were grafted (Figure
S5). Once mice had become near normoglycemic (3 consecutive
days of glycemia levels,120 mg/dL), insulin pellets were removed
and animals followed for an additional 6 to 8 days. Subsequently,
the engrafted kidney was removed and blood glycemia was further
followed up (Figures 4A & 4B).
Six out of 10 and 5 out of 10 mice grafted with 56105 rMAPC
and rHypoSC progeny, respectively, became normoglycemic
between d25–30 and d30–35 respectively (Figures 4A and 4B).
An intraperitoneal glucose tolerance test (GTT) was performed in
mice that received rMAPC (rMAPC-1 n=4; CL19 n=2) and
rHypoSC (Fi2 n= 2; WK8 n=3) progeny once normoglycemia
was achieved. A similar increase and clearance of glucose was seen
as in control non-diabetic mice, in both recipients of rMAPC and
HypoSC progeny (Figures 4C and D). Before nephrectomy, C-
peptide levels in the serum were 2361.9 ng/mL and 2161.6 ng/
mL in recipients of rMAPC or rHypoSC progeny, respectively.
After unilateral nephrectomy, C-peptide levels decreased to that of
STZ-treated mice without cell grafts (Figure S6), and all animals
became hyperglycemic within one day (Figure 4A and 4B).
The grafts contained 6169% and 70611% Pdx1-positive cells,
5666% and 6467% of which co-expressed Nkx6.1 and 4867%
and 5164% C-peptide, respectively in 56105 rMAPC or HypoSC
progeny grafts (Figure 5). In addition, we detected 862% and
1062% glucagon-positive cells and 260.8% and 360.7%
somatostatin-positive cells in rMAPC or HypoSC progeny
recipients (Figure 5). For 360.6% of glucagon and 160.8% of
somatostatin cells, co-expression with C-peptide was seen in both
rMAPC and rHypoSC (Figure S7). However, as there is no
homogenous coexpression of PDX1 with NKX6.1 nor with C-
peptide (Figure 5), we believe the graft is not yet completely
Figure 3. d21 rMAPC and rHypoSC derived progeny release C-peptide in response to glucose in a physiological manner. (A) C-
peptide release in response to different glucose concentrations (5, 10 & 20 mM) and L-Arginine (10 mM) was measured after static incubation of
differentiated rMAPC-1 for one hour. C-peptide release in response to carbachol (100 mM) in the presence of low glucose levels (5 mM) and in
response to a inhibitor of insulin secretion, Nifedipine (50 mM), in the presence of high glucose (20 mM) stimulation were analysed in the
differentiated rMAPC (B) and Fi2 (C). Results shown are mean 6 SEM of 3 independent experiments including 3 replicates per experiment. * p,0.05;
** p,0.01.
doi:10.1371/journal.pone.0063491.g003
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matured as comparable to endogenous islets. Insulin and C-
peptide were co-expressed indicating that the insulin we detect was
de novo synthesized. Normal rat pancreas was used as a control for
the analysis of the graft (Figure S8). In the graft we also analyzed
for the presence of aFP and there were no aFP positive cells
colocalizing with C-peptide were found in vivo.
Discussion
A number of strategies are being explored to increase the b-cell
mass as therapy of T1D, including among others regeneration of
b-cells from intra-pancreatic (ductal) progenitor cells [31],
transdifferentiation of a-cells to b-cells [32], or even transdiffer-
entiation of hepatocytes to b-cells [33]. A number of studies have
been published wherein mouse or human ESC and induced
pluripotent stem cells (iPSC) can be guided in vitro towards DE,
endocrine endoderm, or even near-mature b-cells that upon
grafting in murine models of diabetes, can impact hyperglycemia
[16–20].
Here we used rMAPC [22,26,27] and rHypoSC [25] cells
isolated from rat blastocysts using MAPC culture conditions to
generate endocrine pancreas and b-cell like cells. We have
previously shown that rMAPC [22] and rHypoSC [25] can be
fated towards hepatic endodermal cell types, apparently by
refating the cells from a PrE to ME/DE fate. We demonstrate
here that culture of rMAPC and rHypoSC with 100 ng/mL
activin-A combined with 50 ng/mL BMP4 induces a complement
of marker genes (Gsc, Eomes, Mxl1, Cxcr4, Sox17, and FoxA2) which,
when combined, represents ME/DE. Compared with most
published studies wherein activin-A is added for 3–4 days to
commit ESC to DE, we found that stimulation for up to 9 days
with activin-A was required to generate optimally DE. This could
be consistent with the fact that rMAPC/HypoSC first have to
switch from a more PrE-like phenotype to epiblast-like cells,
thereby gaining the ability to undergo ‘‘gastrulation’’. We have
previously demonstrated a similar phenomenon when inducing
rMAPC to hepatocyte-like cells [22]. It was commonly accepted
that DE derivatives are solely derived from the epiblast. However,
Kwon et al. demonstrated that aside from DE, a significant number
of cells in the gut of 12–18 somite embryos are derived from
visceral endoderm (VE), direct descendants from PrE [34]. Sox7, a
TF typical for PrE and VE and highly expressed in rMAPC and
HypoSC continued to be expressed during differentiation. In
addition, although we expected Glut2 transcripts to be expressed
Figure 4. Reversal of hyperglycemia in the STZ treated mice. Reversal of sustained high blood glucose level in STZ-treated diabetic nude
mice after renal subcapsular implantation of d21 non-attached clusters derived from rMAPC (A) and rHypoSC (B). 6 out of 10 animals transplanted
with rMAPC differentiated to insulin-producing cells achieved normoglycemia (A) and 5 out 10 in rHypoSC group (B). Average of blood glucose
levels in response to intraperitoneal glucose tolerance test for the mice transplanted with differentiated rMAPC (n = 6) (C) and rHypoSCs (n = 4) (D)
and were compared with control mice (n = 4). Data shown are mean 6 SEM of glycemias over time (panels A and B) and of glucose tolerance test
(panel C and D).
doi:10.1371/journal.pone.0063491.g004
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only once insulin-producing cells are being formed, we saw a
significant increase in Glut2 as early as 3 days after the
differentiation protocol was applied. As this coincided with the
induction of aFP, and Glut2 has been described in VE [35], we
believe that the very quick increase in aFP and Glut2, and
persistent expression of Sox7 may be due to default differentiation
of a fraction of the rMAPC/HypoSC to VE. It should be noted
that in contrast to aFP mRNA levels that were .100 fold lower in
the non-attached clusters than the attached cells, Glut2 transcripts
remained expressed in the clusters. Hence, a fraction of the
rMAPC/HypoSC default differentiated to VE, without this
interfering with the generation of endocrine pancreas and
eventually mature b-cell like cells. We detected also some
induction of endothelial-cell specific genes throughout the
differentiation, suggesting that rMAPC and HypoSC generated
mesoendoderm, allowing mesodermal differentiation to follow.
The differentiation protocol used is in some aspects similar to
the protocols used to specify mouse and human ESC or iPSC
towards b-cells, even though significant differences are present as
well. Similar to most differentiation protocols [16–20] initial
commitment to the ME/DE required high concentrations of
activin-A. Presence of fetal calf serum in our differentiation
protocol is likely responsible for the fact that addition of Wnt3a,
known to also play a role in ME/DE commitment [36], was not
required. The first difference between our protocol and recently
developed protocols for ESC/iPSC differentiation towards pan-
creatic endoderm is the positive effect noted with addition of
BMP4 during the initial step of differentiation, whereas others
have reported that inhibiting BMP4 signaling is required to specify
DE to pancreatic and not hepatic endoderm [9,18]. As discussed
above, even though we found expression of aFP from d3 onwards,
this is likely not a reflection of hepatic differentiation, but evidence
of default differentiation towards visceral endoderm. It is possible
that the difference in fate of rMAPC/HypoSC compared with
ESC plays a role in the differential requirement for BMP4.
Alternatively, species differences may be of importance, as
Serafimidis et al. [37], also demonstrated the need for BMP4 in
murine ESC specification towards pancreatic endoderm. It is well
known that significant differences exist in the requirements for
growth factors from the TGFb family, and in particular BMP4, for
ESC maintenance from different species. Hence, the requirement
for BMP4 for lineage specification may also be species-dependent.
The second difference between the protocol used for rMAPC/
HypSC differentiation and published protocols are that we could
not detect an effect of retinoic acid on pancreatic endoderm
commitment.
As in most studies, the in vitro differentiated progeny from
rMAPC and rHypoSC were mixed populations of ‘‘immature’’ b-
cell like cells. We detected Somatostatin, Ghrelin, Ins1 and Ins2
transcripts, but could not detect Glucagon transcripts in vitro.
Between 5 and 10% of the in vitro differentiated progeny expressed
C-peptide. Such cells are likely still immature because MafA
Figure 5. Immunofluorescence analysis of the graft. Micrographs from serial sections of the graft from the mice transplanted with
differentiated rMAPC (A) and rHypoSC (B) were double stained for the analysis of colocalization for the pancreatic proteins Nkx6.1 and Pdx1, C-
peptide and Pdx1, C-peptide and Insulin. All C-peptide positive were also insulin positive. Grafts were also analysed for the expression of other islet
hormones, glucagon and somatostatin. Scale bar, 50 mm.
doi:10.1371/journal.pone.0063491.g005
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protein was expressed perinuclear, as has been described for
neonatal rat b-cells [28]. Nevertheless, we demonstrated that the
b-cell like cells in the d21 progeny secrete C-peptide in response to
both glucose and L-arginine as well as in response to the addition
of carbachol [29] and secretion is blocked by the Ca2+ antagonist
nifedipine [30].
Final proof that functional b-cell like cells have been generated
is demonstrated by studies wherein the grafted cells rescue animals
that are hyperglycemic. Studies on islet from different species have
recognized that the cytoarchitecture of pancreatic islets differs
between species. In particular, rodent islets are composed of 80%
b cells, 10% a cells, ,8% d cells, and ,2% PP cells.
Immunofluorescence analysis of rodent islets showed unique
arrangement of hormone producing cells in that the insulin-
expressing cells being clustered in the core of the islets and the
non-beta-cells, including alpha-, delta- and PP-cells, form the
mantle region (37). When 56105 islet cells (corresponding to
approximately 500 mature islets) are grafted in STZ-diabetic mice,
an immediate return to normoglycemia is observed. However,
following grafting of 56105 rMAPC and HypoSC progeny,
normoglycemia did not return for approximately 1 month. This is
consistent with the fact that although the cells that were
transplanted contained .90% FoxA2-positive-endoderm cells
(64.56105 cells) and 21% Pdx1-positive pancreatic endoderm
cells (6105 cells), they contained only 7% C-peptide-positive cells
(0.356105 cells).
It is thus very likely that additional b-cell like cells needed were
generated from the FoxA2 and/or Pdx1-positive fraction in vivo to
eventually correct the hyperglycemia. Consistent with this, we
could also detect glucagon-positive cells in the graft, but not in the
in vitro generated progeny. Therefore we believe that FoxA2 and/
or Pdx1-positive cells matured in vivo, generating cells expressing
the three major endocrine hormones, even though a fraction of the
cells still were C-peptide and glucagon double positive, and hence
not yet fully mature (Figure S7). Nevertheless, the b-cell-like cells
present in the graft in vivo could handle glucose in a physiological
manner, as glucose disposal in vivo following glucose tolerance test
was highly similar as in non-diabetic mice. Upon removal of the
graft, wherein no tumors were found, all animals became
hyperglycemic again.
In conclusion, we here demonstrate again that cells that have a
nascent hypoblast phenotype, can in vitro be fated to generate
intraembryonic endoderm (and mesoderm), via an intermediate
ME/DE stage. This occurs combined with initial default
differentiation towards visceral endoderm. Nevertheless, once
committed to ME/DE, cells can be further specified to pancreatic
endoderm and (immature) b-cell-like cells. When grafted in vivo,
the mixed progeny transplanted under the kidney capsule of STZ-
induced diabetic mice can reverse hyperglycemia, and this by
producing physiological amounts of insulin for a given glucose
load. Extension of this protocol to other ‘‘pluri’’potent stem cells
will be of interest. In addition studies aimed at isolating human
HypoSCs may provide an alternative cell source that can relatively
robustly differentiate into glucose responsive insulin-producing b-
cell like cells.
Supporting Information
Figure S1 Standardization of the differentiation proto-
col. (A) RT-qPCR analysis showing the expression of Pdx1 after
the stimulation of rMAPC-1 using different combination of
cytokines. Only the combination of Activin-A (100 ng/mL) and
BMP-4 (50 ng/mL), together with the inhibition of Shh, was able
to up-regulate the expression of Pdx1. (B) Expansion of the Pdx1
positive cells with EGF, HGF, FGF-10 or betacellulin (50 ng/mL)
starting from rMAPC-1 cultured for 6-9 days with Activin
A+BMP-4+anti-Shh (stages 1 & 2). (C) RT-qPCR results for
Pdx1 and Ins1 & Ins2 on rMAPC-1 cultured with different
combinations of Nicotinamide (10 mM), Exendin-4 (10 nM), BTC
(50 ng/mL) and GDF-11 (50 ng/mL) during the last step of
differentiation. Pdx1 and Ins1/2 mRNA levels are expressed in %
versus a positive control (rat pancreas) and were normalized by
using GAPDH as housekeeping gene. RT-qPCR results are
expressed as mean (6 SEM) of experiments performed in
triplicates. * p,0.05; ** p,0.01; ***p,0.001.
(TIF)
Figure S2 Pdx1 protein expression analysis on cell-
clusters derived from rMAPCs. (A) Intracellular FACS
analysis showing the expression of Pdx1 in d 21 cell clusters
generated by rMAPC-1. Pdx1 expression is compared to
undifferentiated rMAPC and the insulinoma cell line RINm5F.
(B) Confirmation of Pdx1 expression on d21 rMAPC cell clusters
by western blot analysis.
(TIF)
Figure S3 Expression analysis of hepatic and mesoder-
mal lineage genes during the course of differentiation of
rMAPC. mRNA expression of hepatic (A) and mesodermal (B)
lineage genes was quantified by RT-qPCR analysis. Data shown
are the average of three independent experiments.
(TIF)
Figure S4 C-peptide release by rMAPC progeny during
the course of differentiation. C-peptide secretion after one
hour incubation with 20 mM glucose during the last 9 days (forth
step+3 days) of the differentiation protocol was analyzed using rat
C-peptide specific ELISA kit. The results shown are the average
of three independent experiments. SEM6, n = 3 experiments.
* p,0.05, ** p,0.01.
(TIF)
Figure S5 Analysis of body weight of the grafted
animals. Body weight of mice transplanted with differentiated
rMAPC (n= 6) and rHypoSC (n= 4) were monitored up to 45
days post transplantation. Data shown is mean 6SEM of the
weight.
(TIF)
Figure S6 In vivo C-peptide analysis in mice trans-
planted with differentiated cells. Pre- and post-nephrecto-
mized C-peptide release was measured in the serum of mice
transplanted with differentiated (A) rMAPC (n= 6) and (B)
rHypoSC (n= 4). Data shown is mean6SEM. ** p,0.01.
(TIF)
Figure S7 Immunohistological analysis of the graft. In
some areas of the graft, colocalization of C-peptide and glucagon
in both rMAPC and rHypoSC progeny was detected, indicating
persistence of some immature hormone expressing cells. Scale
bar = 50 mM.
(TIF)
Figure S8 Immunohistological analysis of normal rat
pancreas. As a positive control for the antibodies used for
staining, normal rat pancreas were stained for islet hormones C-
peptide and insulin and for transcription factors PDX1 and
NKX6.1 along with nuclear specific staining using DAPI. Scale
bar = 50 mM.
(TIF)
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Table S1 Quantitative PCR analysis of genes expressed
during the course of differentiation of rMAPC1 to b-cell
like cells (n= 3 experiments, ±SD).
(DOCX)
Table S2 Quantitative PCR analysis of genes expressed
during the course of differentiation of CL19 to b-cell like
cells (n=3 experiments, ±SD).
(DOCX)
Table S3 Quantitative PCR analysis of genes expressed
during the course of differentiation of HypoSC to b-cell
like cells (n= 3 experiments (Fi-1= 2n and WK8=1n)
±SD).
(DOCX)
Table S4 Primer sequences used for the transcript
detection by RT-qPCR.
(DOCX)
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